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Available online 22 September 2011AbstractBackground: Chemoradiotherapy is increasingly applied in patients with oesophageal cancer. The aim of the present study was to determine
whether 3D-CT volumetry is able to differentiate between responding and non-responding oesophageal tumours early in the course of neo-
adjuvant chemoradiotherapy.
Patients and methods: Serial CT before and after two weeks of neoadjuvant chemoradiotherapy was performed in the multimodality treat-
ment arm of a randomised trial including patients with oesophageal carcinoma. CT response was measured with the change in tumour vol-
ume between baseline and after 14 days of neoadjuvant therapy. Receiver Operating Characteristic (ROC) analysis was used to evaluate the
ability of 3D-CT as an early imaging marker of response.
Results: CT response analysis was performed in 39 patients, of whom 26 patients were histopathological responders. Median tumour vol-
ume increased between baseline and after 14 days of chemoradiotherapy in histopathological responders as well as in non-responders,
though changes were not statistically significant. The area under the ROC curve was 0.71.
Conclusion: Tumour volume changes after 14 days of neoadjuvant chemoradiotherapy as measured by 3D-CT were not associated with
histopathological tumour response. CT volumetry should not be used for early response assessment in patients with potentially curable
oesophageal cancer treated with neoadjuvant chemoradiotherapy.
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 2011 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
Most studies investigating early response to neoadjuvant
therapy in patients with oesophageal cancer have focused
on evaluation of 18F-fluoro-deoxyglucose positron emis-
sion tomography (FDG-PET), as described in several small
studies and in one large phase II trial, with promising re-
sults.1e3 However, FDG-PET is commonly not used as rou-
tine staging modality.4 It would therefore be more efficient
if one of the routine staging modalities (CT or endoscopic
ultrasound) was able to predict histopathological response.* Corresponding author. Tel.: þ31 20 5666676; fax: þ31 20 5669243.
E-mail addresses: m.vanheijl@amc.uva.nl, m.vanheijl@umcutrecht.nl
(M. van Heijl).
doi:10.1016/j.ejso.2011.09.004
0748-7983  2011 Elsevier Ltd. Open access under the Elsevier OA license.Response monitoring using 3D-CT volumetry in patients
with oesophageal cancer is a relatively new technique. The
ability of computed tomography (CT) in this field seemed
limited, according to studies investigating early response to
neoadjuvant chemoradiotherapy by CT using tumour diame-
ter or T-stage as parameters.5,6 A recently published study
using tumour volumetry based onCT for early response eval-
uation in patients treated with neoadjuvant chemotherapy
without radiotherapy did, however, show a sensitivity of
100%, in a relatively small series of patients.7
Before a new technology is introduced in practice, one
has tot demonstrate that it has sufficient reliability. For
that purpose, we also wanted to evaluate the between-
reader reproducibility and within-reader reproducibility of
3D-CT volume measurements. We then evaluated to what
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histopathological responders and non-responders early dur-
ing neoadjuvant chemoradiotherapy.Patients and methods
Study design
In September 2004 a multicentre randomised phase-III
trial (175 patients in each arm) was initiated in the Nether-
lands, comparing neoadjuvant chemoradiotherapy followed
by surgery with surgery alone in patients with potentially
curable oesophageal cancer. Details of the study design
were reported previously.8 The study was approved by the
Medical Ethics Committee.
Patients willing to undergo an extra CT-scan after two
weeks of therapy were included in the present study.9PatientsPatients included in the present study participated in the
neoadjuvant arm of a randomised controlled trial and had
histologically proven squamous cell carcinoma or adeno-
carcinoma of the oesophagus or gastro-oesophageal junc-
tion. Inclusion criteria regarding clinical TNM stage
were: T1-3 N0-1 M0-M1a, excluding only T1N0. All pa-
tients underwent extensive preoperative workup including
endosonography, external ultrasonography of the neck and
CT-scan of chest and abdomen. Tumours did not extend
more than 4 cm into the gastric cardia, longitudinal tumour
length was <8 cm and radial size <5 cm cT1N0 tumours
were not eligible. In the absence of local irresectability
and/or distant dissemination patients with an acceptable
general condition (ECOG performance status 0, 1, 2;
weight loss < 10%) were invited to participate in the rand-
omised trial. After written, voluntary, informed consent and
stratification for tumour type, treatment centre, clinical
lymph node status, and WHO performance the patients
were randomised between the two treatment-arms (neoad-
juvant chemoradiation followed by surgery versus surgery
alone). Patients who were randomly allocated to the neoad-
juvant arm were subsequently asked to participate in the
present study. For the current analysis only patients treated
in the Academic Medical Centre in Amsterdam were
included.Neoadjuvant concurrent chemoradiotherapyOver a 5 week period concurrent chemoradiotherapy
was applied on an outpatient basis. Paclitaxel (50 mg/m2)
and carboplatin (area-under-curve ¼ 2) were administered
by i.v. infusion on days 1, 8, 15, 22, and 29. External
beam radiation with a total dose of 41.4 Gy was given in
23 fractions of 1.8 Gy, 5 fractions a week, starting the first
day of chemotherapy. Radiation therapy was delivered us-
ing a multiple field technique.SurgeryOesophagectomy was performed within 6 weeks after
completion of chemoradiation. For tumours proximal to
the gastro-oesophageal junction a transthoracic oesopha-
geal resection with a two field lymph node dissection was
preferred. For tumours involving the gastro-oesophageal
junction without suspected lymph nodes in the upper part
of the chest a transhiatal oesophageal resection was pre-
ferred. All surgical procedures were carried out using an
open approach.Evaluation of tumour response by spiral CTCT scans were obtained at baseline and at day 15 during
neoadjuvant chemoradiotherapy. A target CT was per-
formed using a multi-slice CT scanner (minimal four-
slice CT-scanner) after administration of 100 ml low osmo-
lar intravenous contrast medium. After a 25 s delay a spiral
scan CT was performed targeted at the oesophagus and oe-
sophagogastric junction including the maximum extension
of the tumour (maximum slice thickness 3 mm, maximum
pitch  1.5, 150 mAs) with inferior-superior scanning.
Scan settings concerning spatial resolution and contrast
timing were identical for pre- and post-treatment CT-scans.
The tumour area was calculated quantitatively by 3D vol-
ume measurement. Image analysis necessary for these vol-
ume measurements was performed by three readers. Reader
1 (SSKSP) was an experienced gastrointestinal radiologist,
reader 2 (BMM) was a gastrointestinal radiologist with in-
termediate experience and reader 3 (MvH) was a surgical
research fellow with no prior radiological experience but
was trained for this specific task. To perform tumour volu-
metry MxView V 3.52 software was used (Philips Medical
Systems, Best, the Netherlands). The reader defined the
contour of the tumour on every slice on which the tumour
was visible, excluding the oesophageal lumen. (Fig. 1A)
Subsequently the computer-program created a 3D image
of the tumour and calculated the tumour volume. (Fig. 1B).
A learning session was held with all three readers prior
to the study measurements. During this session ten tumour
volume measurements were performed together to achieve
optimal agreement in the methods.Histopathological responseThe clinical reference standard for the post-
chemoradiation disease stage was based on the histology
in the surgical resection specimen. The whole tumour as
well as proximal and distal resection margins were in-
cluded. Slices from the oesophageal part of the tumour
were made horizontally while the gastro-oesophageal junc-
tion slices were made longitudinally. One slice was per-
formed every 4 mm. If no tumour was found in the
suspected location additional slices were made of the rest
of the oesophagus to confirm complete response. Treatment
Figure 1. A. tumour contour drawn in one CT-slice and B. 3D reconstructed tumour volume.
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which is based on the percentage of viable residual tumour
cells in relation to fibrosis/necrosis.10 Responders were de-
fined as patients with Mandard grade 1 representing com-
plete response and grade 2 representing < 10% viable
residual tumour cells; non-responders were defined as pa-
tients with grade 3 (>10% viable residual tumour cells)
or grade 4 (no sign of response). One highly experienced
gastrointestinal pathologist (FJWtK) examined the pathol-
ogy specimens.AnalysisReceiver Operating Characteristic (ROC) curves were
constructed to evaluate the ability of 3D-CT volumetry to
identify histopathological response and the area under the
curves and their 95% confidence interval were calculated.
ROC curves were drawn for each reader separately and
for the mean measurements of all three readers. Using the
ROC curve of the mean measurements of all three readers,
the effects of several cut-off points (0%, 10%, and 20%) on
diagnostic parameters were calculated. Interobserver repro-
ducibility was illustrated by scatter plots comparing the CT
volume measurements obtained by each of the three radio-
logical readers. The intraclass correlation coefficient (ICC)
was used to quantify to what extent differences in measure-
ment were due to genuine differences rather than between-
reader differences or chance. Intraobserver reproducibility
was estimated based on repeating the measurements made
by one reader (reader 3), after an interval of at least 3
months. Scatter plots were again made and ICC’s
calculated.Results
In a series of 28 men and 11 women with oesophageal
cancer participating in the randomised trial two sequential
CT-scans were performed before start and after 14 days
of neoadjuvant chemoradiotherapy in the Academic Medi-
cal Centre.Baseline characteristicsThe baseline patient and tumour characteristics are sum-
marised in Table 1, with patients classified as either histo-
pathological responders or non-responders. A tumour
volume increase was observed in both groups after 14
days of chemoradiotherapy, with a relatively higher in-
crease in the histopathological non-responding patients
(22%), however not significantly different compared to
the responders (12%).ROC analysis and diagnostic parametersROC curves for identifying histopathologic responders
based on changes in CT volume measurements before
and after 14 days of neoadjuvant chemoradiotherapy are
shown in Fig. 2. Only the curve of reader 2 was signifi-
cantly different from chance, with an area under the curve
of 0.71. The individual data in Table 2 show that the major-
ity of histopathological responders had an increase of tu-
mour volume as measured by CT at the start and after 14
days of chemoradiotherapy. Effects of various CT volume
change cut-off values on diagnostic parameters using the
mean measurements of all three readers are summarised
in Table 3.Interobserver analysisComparison of pretreatment measurements (ICC 0.90) of
reader 1 vs. 3 showed excellent reproducibility and for the
volume measurements after 14 days of CRT (ICC 0.80)
good reproducibility. The reproducibility of the pretreatment
measurements of reader 1 vs. 2 (ICC 0.50) and reader 2 vs. 3
(ICC 0.49) were moderate. The reproducibility of the mea-
surements after 14 days of CRT of reader 1 vs. 2 (ICC
0.53) and reader 2 vs. 3 (ICC 0.41) were also moderate.Intraobserver analysisFor the purpose of an intraobserver analysis reader 3
performed all measurements twice and showed good
Table 1
Patient and tumour characteristics. Patients were subdivided into histopathological responders (Mandard score 1 or 2 in the surgical resection specimen) and
non-responders (Mandard score 3 or 4).
Characteristic Assessable patients for CT response analysis (N ¼ 39) P-value
Histopathologic responders Histopathologic non-responders
No. 26 (67%) 13 (33%) e
Age (mean) [range] 62 [38 to 76] 56 [37 to 73] 0.09
Gender
Male (%) 18 (69) 10 (77) 0.72
Female (%) 8 (31) 3 (23)
Histological type
AC (%) 20 (77) 13 (100) 0.08
SCC (%) 6 (23) 0 (0)
cT-stage (%)
T1 0 (0) 0 (0) 0.59
T2 2 (8) 2 (15)
T3 24 (92) 11 (85)
cN stage(%)
N0 6 (23) 4 (31) 0.70
N1 20 (77) 9 (69)
CT-parameters
CT Volume 1a (median) [IQR] 37 [24 to 48] 33 [18 to 59] 0.63
CT Volume 2a (median) [IQR] 40 [31 to 58] 41 [31 to 66] 0.77
Change CT Volume (%) (median) [IQR] 12 [-4 to 28] 22 [1 to 46] 0.18
AC adenocarcinoma; SCC squamous cell carcinoma; cT pretreatment clinical T-stage; cN pretreatment clinical N-stage; CT computed tomography; IQR
interquartile range CT volume 1 ¼ pretreatment CT volume; CT volume 2 ¼ CT volume after 2 weeks of chemoradiotherapy.
a Median and range of mean measurements by all three readers.
1067M. van Heijl et al. / EJSO 37 (2011) 1064e1071consistency both in the pretreatment measurement (ICC
0.92) and in the measurement after 14 days of chemoradio-
therapy (ICC 0.79).
DiscussionImportance of response monitoringNeoadjuvant chemoradiotherapy before surgery can im-
prove survival in patients with potentially curable oesopha-
geal cancer, but not all patients respond.11e15 This study
investigated whether decrease in tumour volume as mea-
sured by 3D-CT is able to identify histopathological re-
sponse to neoadjuvant chemoradiotherapy in patients with
potentially curable oesophageal cancer. In this study, a ma-
jority of all histopathological responders showed an in-
crease of tumour volume as measured by 3D-CT between
start and after 14 days of chemoradiotherapy. These find-
ings shed doubt on the prior hypothesis that a tumour vol-
ume decrease as measured by 3D-CT during
chemoradiotherapy is associated with histopathological
response.Clinical value of CTAlthough FDG-PET seems most promising for this
purpose,3,16e18 some authors have suggested CT could
also be used.7,19 The first study compared decrease of var-
ious tumour diameters on spiral CT with response to che-
motherapy as assessed by endoscopy and found a highcorrelation.19 Unfortunately, no data about the objective re-
sponse in the resection specimen was reported. Further-
more, neoadjuvant chemotherapy without radiotherapy
was applied in that series of patients, which might at least
partly explain the difference with the findings in the present
study. As in the present study, the group of Beer et al. ap-
plied 3D tumour volumetry to assess tumour response, but
again only chemotherapy without radiotherapy was ap-
plied.7 Raw data of 18 patients were presented, with
a mean decrease of 24% in tumour volume in histopatho-
logical responders and a mean decrease of 16% in the
non-responding patients, a difference that was not statisti-
cally significant. Strikingly, in that series none of these pa-
tients showed an increase in tumour volume. Using a cut-
off level of 14.8% tumour reduction, a sensitivity of
100%, specificity of 53%, positive predictive value of
46% and negative predictive value of 100% were achieved.
The use of a comparable cut-off value of 10% in the present
study (Table 3) resulted in especially low sensitivity (19%)
and negative predictive value (36%). The fact that the ex-
cellent results of Beer et al. were not obtained in the present
study is probably due to the additional application of radio-
therapy.20 The local inflammatory response to radiation
probably caused the visualized tumour volume to increase
and not to decrease. Moreover, this seems to occur indepen-
dently from histopathological tumour response to therapy.
An earlier published study investigated CT measurements
of tumour volume in 45 patients with squamous cell carci-
noma before and after neoadjuvant chemotherapy.21 No sig-
nificant association was found between volume decrease
Figure 2. Receiver Operating Characteristic (ROC) curves for the assessment of histopathologic response using CT volume measurements of Readers 1, 2 and
3. A. Area Under the Curve for Reader 1: 0.60 (95% confidence interval 0.39e0.81) B. Area Under the Curve for Reader 2: 0.71 (95% confidence interval
0.55e0.87) C. Area Under the Curve for Reader 3: 0.62 (95% confidence interval 0.43e0.81) D. Area Under the Curve for mean of all three readers: 0.63
(95% confidence interval 0.45e0.82).
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patients a decrease in tumour volume was observed, which
is in great contrast to the results of the present study.
In an other study investigating tumour response to neo-
adjuvant chemoradiotherapy in patients with oesophageal
cancer using CT the tumour volume was determined by
multiplying tumour length by depth and it was demon-
strated that CT was unable to predict therapeutic re-
sponses.22 A disadvantage of the CT evaluation in that
study was that scanning proceeded with 10 mm collimation
and 10 mm image reconstruction that could have rendered
measurements of tumour volume inaccurate. It was how-
ever also reported that fibrous tissue or oedema locatedaround the tumour could also have affected measurements
of residual tumours.Interobserver variationIn the present study, we also performed an interobserver
and intraobserver analysis to assess the reproducibility of
this relatively new technique. Two readers were able to
achieve a relatively high interobserver agreement and one
reader who performed all measurements twice also
achieved an excellent intraobserver agreement. Our data in-
dicate that adequate reproducibility of 3D-CT tumour vol-
ume measurements can be achieved. In the interobserver
Table 2














mean of all readers
1 Non-responder 137 121 67 102
2 Non-responder 84 140 123 113
3 Non-responder 67 9 5 22
4 Non-responder 60 26 26 37
5 Non-responder 48 63 57 56
6 Non-responder 48 35 10 33
7 Non-responder 27 22 12 20
8 Non-responder 21 27 52 31
9 Non-responder 14 3 28 3
10 Non-responder 14 18 18 17
11 Non-responder 12 1 4 5
12 Non-responder 34 5 9 16
13 Non-responder 96 1 66 5
14 Responder 131 17 16 45
15 Responder 87 52 78 71
16 Responder 48 186 28 88
17 Responder 42 19 48 38
18 Responder 41 18 20 9
19 Responder 37 10 55 22
20 Responder 36 22 15 0,9
21 Responder 34 22 11 23
22 Responder 28 4 73 28
23 Responder 27 3 15 15
24 Responder 26 7 45 15
25 Responder 26 4 12 8
26 Responder 25 71 12 28
27 Responder 22 13 16 5
28 Responder 21 28 16 23
29 Responder 21 226 26 56
30 Responder 13 12 9 3
31 Responder 9 0,5 37 14
32 Responder 1 26 4 17
33 Responder 2 7 6 4
34 Responder 3 3 5 4
35 Responder 5 14 16 12
36 Responder 6 10 3 4
37 Responder 14 20 32 22
38 Responder 16 9 43 15
39 Responder 18 14 29 20
a Positive value equals volume increase; negative value equals volume decrease.
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agreement in their measurements, while the measurements
of reader 2 showed less agreement to those of reader 1 and
3. As mentioned in the methods section, reader 3 was a sur-
gical research fellow with no prior radiological experienceTable 3
Effects of various CT volume change cut-off values on diagnostic param-
eters for early response assessment using the mean measurements of all
three readers.
Diagnostic parameter Cut-off 0% Cut-off 10% Cut-off 20%
Sensitivity % (n/N) 35 (9/26) 19 (5/26) 8 (2/26)
Specificity % (n/N) 77 (10/13) 92 (12/13) 100 (13/13)
PPV % (n/N) 75 (9/12) 83 (5/6) 100 (2/2)
NPV% (n/N) 37 (10/27) 36 (12/33) 35 (13/37)
PPV positive predictive value; NPV negative predictive value.who was trained for this specific task. The training was per-
formed by reader 1, a highly experienced gastrointestinal
radiologist. This is probably the reason why reader 1 and
3 have such high agreement in the interobserver analysis.
After the training a feedback session was held with all three
readers, to discuss agreement. Despite these preparations
there still was a significant difference between the measure-
ments of reader 2 and the measurements of reader 1 and 3.
We believe this suggests that high reproducibility can be
achieved but that this takes more effort.
In a few cases extremely different judgements were ob-
served between the three readers: cases 3, 13, 14, 16 and
29. These cases were further analysed to find a reason for
these different results. It turned out that all these patients
had distal oesophageal tumours extending into the cardia.
As generally known it is even harder to differentiate
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ach compared to the oesophagus at CT. The observers had
to choose either to include the abnormal wall thickening in
the cardia into the tumour volume or to discard this as non-
malignant wall thickening due to chemo(radio)therapy in-
duced gastritis.
In a study performed approximately 10 years ago the
claimed interobserver correlation for CT tumour volume
measurements was very high (n ¼ 19; inter-rater reliability
0.96). Unfortunately, the authors did not clarify whether the
pre- or post-treatment measurements were used for this in-
terobserver analysis.21 Observer variation was also assessed
by Beer et al., and was highly comparable to those of the
present study.7 The present results add that the technique
was also very robust in inexperienced hands, as the mea-
surements of the surgical research fellow (reader 3) were
highly reproducible.Clinical value of FDG-PETAs mentioned, most reports on (early) response assess-
ment to chemoradiotherapy focus on FDG-PET as distin-
guishing modality. Results of available studies are
however contradictory. Two of these studies suggested
that FDG-PET may be used for early response assess-
ment.18,23 The study by Wieder et al. was performed in
23 patients with squamous cell carcinomas and reported
an 88% negative predictive value, which suggests clinical
applicability of FDG-PET.18 Two other studies investigat-
ing this specific subject show opposite results, suggesting
that FDG-PET fails to predict response early during neoad-
juvant chemoradiotherapy.24,25 One of these studies
(n ¼ 100) was recently performed in our centre and showed
that even if a liberal cut-off point of 0% SUV decrease was
used, FDG-PET was not able to achieve a negative predic-
tive value higher than 75%.25 In clinical practice, this
would mean that a quarter of the patients who do not
show response according to FDG-PET would then errone-
ously discontinue potentially effective chemoradiotherapy.
Two other studies in which the decrease in FDG-uptake af-
ter completion of neoadjuvant therapy was investigated for
prediction of histopathological response also showed nega-
tive results.26,27Histopathological responseThe scoring system used for histopathological response
in the present study was based on the principles of the orig-
inal Mandard-scoring system, however modified to a scor-
ing system defined by 4 tumour regression grades instead
of the 5 which are used in the original Mandard score.
Most other reported reliable scoring systems are also mod-
ified from the original Mandard-scoring system, which is
based on the proportion of residual vital tumour cells after
chemoradiotherapy. One of these alternative scoring sys-
tems commonly used is described by Chirieac et al. andalso by Schneider et al.28,29 This scoring system also con-
sists of 4 grades, just like the system used in the present
study. The cut-off values are however different: grade 1
shows >50% vital residual tumour cells; grade 2 shows
10%e50% vital residual tumour cells; grade 3 shows
<10% vital residual tumour cells; and grade 4 is a complete
response with 0% vital residual tumour cells. This scoring
system was significantly correlated with survival.LimitationsThere are some limitations that need to be acknowl-
edged and addressed regarding this study. First, despite
the fact that the present study is the first study investigating
response assessment early during neoadjuvant chemoradio-
therapy in patients with oesophageal cancer, the number of
included patients is relatively low. It is, however, unlikely
that a larger number of patients would change the outcome
of the study. Secondly, no reference standard was available
for tumour volume measurements, as has for example been
described e.g. by Griffith et al. who used a peroperative wa-
ter displacement method.21 It is unclear whether this
method can actually be used as reference standard, because
the tumour volume is of course susceptible for chemo(ra-
dio)therapy and probably fluctuates over time.Conclusion
In conclusion, early identification with 3D-CT volume-
try of responders after 14 days of neoadjuvant chemoradio-
therapy is not reliable. Change in tumour volume as
measured by 3D-CT volumetry was not associated with his-
topathological tumour response. In a series of patients of
whom the great majority showed histopathological re-
sponse, the median tumour volume paradoxically in-
creased. Consequently, no realistic optimum cut-off value
for tumour volume decrease could be identified. Therefore,
CT should not be used for early response assessment in pa-
tients with potentially curable oesophageal cancer who are
treated with neoadjuvant chemoradiotherapy.Role of the funding source
The funding source (Zon-Mw) is a Dutch semi-
government organisation which approved of the original
study-protocol and had further no influence on data collec-
tion, data analysis or data interpretation. (Zon Mw Health
Care Efficiency Research Grant: 945-04-510).Conflict of interest
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